FDA is celebrating a major review milestone for generic drugs, but the reality remains that much of that weight has yet to come off the agency's shoulders.
A memo from Center for Drug Evaluation and Research Director Janet Woodcock released July 11 trumpeted the achievement: as of July 1 FDA had reviewed more than 90% of the official generic drug user fee
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?